Houston organizations snag chunk of recently announced $49M cancer research grant funding

show me the money

Here's what Houston organizations are benefitting from the latest CPRIT funding announcement. Photo via Getty Images

Houston’s Baylor College of Medicine is beefing up its team of cancer researchers.

The college just received $6 million from the state agency Cancer Prevention and Research Institute of Texas (CPRIT) to recruit three cancer researchers: Graham Erwin, Michael Robertson and Dr. Varun Venkataramani. Each researcher is getting $2 million.

In addition, the University of Texas MD Anderson Cancer Center snagged a $2 million CPRIT grant to recruit Simon Eschweiler.

In all, CPRIT recently announced $49 million in cancer research and prevention grants, including nearly $24 million for recruitment of cancer researchers.

Here’s a rundown of the recruitment grants awarded in Houston:

  • Graham Erwin. Erwin is a postdoctoral fellow at Stanford University’s Stanford Cancer Institute. He’s a biologist who specializes in DNA sequencing related to the development of cancer therapeutics and diagnostics.
  • Michael Robertson. Robertson also is a postdoctoral fellow at Stanford. He focuses on molecular and cellular physiology at Stanford’s medical school.
  • Dr. Varun Venkataramani. Venkataramani, a neuroscientist, is a brain tumor researcher at University Hospital Heidelberg, one of the largest hospitals in Germany.
  • Simon Eschweiler. Eschweiler is a research assistant professor at Southern California’s La Jolla Institute for Immunology. He specializes in immunotherapy for cancer patients.

Aside from the recruitment grants, three institutions in the Houston area received nearly $6 million in funding for cancer treatment and prevention programs. Here’s an overview of those grants:

  • Almost $2.5 million for expansion of a program at the University of Texas Medical Branch at Galveston that supplies HPV vaccinations for new mothers.
  • Nearly $2.5 million for an MD Anderson program that promotes physical activity for cancer survivors.
  • Almost $500,000 for an MD Anderson program to increase treatment of tobacco users who are participating in opioid treatment programs.
  • Nearly $500,000 for a University of Houston program designed to help LGBTQ+ Texans lead tobacco-free lives.

“From new research programs, recruitment of preeminent scientists to Texas, pilot studies, new technology, and expanding the reach of successful cancer prevention programs, [the] grants highlight the effect CPRIT is having on not just cancer research and prevention efforts, but on life science infrastructure in Texas,” Wayne Roberts, the organization’s CEO, said in a news release.

From Your Site Articles
OncoResponse in partnership with MD Anderson Cancer Center received a portion of $73 million the Cancer Prevention and Research Institute of Texas has doled out this spring. Photo via oncoresponse.com

Seattle biotech co. to move to Houston thanks to $13.3M grant from Texas organization

CPRIT funding spotted

A biotech company has landed a more than $13 million grant from the Cancer Prevention and Research Institute of Texas.

The nearly $13.3 million grant given to OncoResponse — which is relocating from Seattle to Houston, according to CPRIT's news release — will help the company develop fully human monoclonal antibodies for treatment of cancer that otherwise would not respond to immunotherapy. OncoResponse already has a partnership with MD Anderson Cancer Center, which is one of the company’s investors.

“We are thrilled to receive this recognition from CPRIT in supporting the potential of our immunotherapy candidate OR502. We greatly appreciate the additional support from our investors as we continue to make significant progress with our drug development efforts advancing immunotherapies derived from clues of Elite Responders,” says Clifford Stocks, CEO of OncoResponse, in a news release.

Aside from the grant, OncoResponse just hauled in $14 million from existing investors in a round led by RiverVest Venture Partners. Other participants in the series D round include Venture Partners, Canaan Partners, 3B Future Health Fund, Bering Capital, Takeda Ventures, and InterVest Capital Partners.

To date, OncoResponse has raised more than $180 million, according to market research company CB Insights.

A representative of OncoResponse couldn’t be reached for comment about the company’s relocation to Houston.

MD Anderson and Seattle-based Theraclone Sciences launched OncoResponse in 2015. Rice University was among the inaugural investors.

OncoResponse’s OR2805 immunotherapy product is being evaluated in a Phase 1 clinical trial. It’s the company’s leading immunotherapy candidate. OncoResponse is also working on OR502, an antibody being prepared for investigational and clinical studies.

“The modern treatment of cancer activates the body’s own immune system to attack cancer,” OncoResponse says in a summary posted on the website of the Cancer Prevention and Research Institute of Texas (CPRIT).

“These treatments, called immunotherapy, may not be successful if the cancer can recruit bad-acting cells, such as tumor associated macrophages, or TAMs, that create barriers preventing immunotherapies from activating the body’s own defenses against the cancer. To find drugs that may help counteract these TAMs, OncoResponse looked to patients who had responded very well to immunotherapy to see if their bodies made factors to block TAMs and helped them fight their cancers.”

OncoResponse’s OR502 prevents TAMs from shutting down the body’s response to cancer, thus restoring tumor-killing immune activity, CPRIT explains.

In addition to OncoResponse, recent CPRIT grant recipients from the Houston area are:

  • Houston-based 7 Hills Pharma, $13,439,001. The company is working on immunotherapies for treatment of cancer and prevention of infectious diseases.
  • Houston-based Allterum Therapeutics, $11,721,150. The company is coming up with an antibody for treatment of patients with acute lymphoblastic leukemia. This type of cancer affects blood and bone marrow.
  • Houston-based Cell Therapy Manufacturing Center, $9.1 million. The center is a joint venture between National Resilience and MD Anderson Cancer Center that is developing cell therapy manufacturing technologies to support biotech partnerships.
  • Houston-based Pulmotect, $8,851,165. The company’s PUL-042 product is aimed at treating and preventing respiratory complications in cancer patients.
  • Cancer researcher Michael King, $6 million. The grant helped lure King to Rice from Nashville’s Vanderbilt University, where he’s been the chair of biomedical engineering. King’s lab at Vanderbilt has been testing therapies for metastatic breast cancer and prostate cancer.
  • Missouri City-based OmniNano Pharmaceuticals, $2,711,437. The pharmatech company is working on two drugs for treatment of solid tumors in patients with pancreatic cancer.

“Texas is unique because of CPRIT’s ability to invest in cutting-edge research when private capital is scarce. This is yet another way Texas is leading the nation in the fight against cancer,” Wayne Roberts, CEO of CPRIT, says in a news release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston space tech co. revises timeline for commercial space station development with NASA partnership

new game plan

Houston-based Axiom Space is accelerating its development of a commercial space station.

NASA awarded Axiom a contract in January 2020 to develop a space station for commercial use. Initially, the station was supposed to be attached to the International Space Station. Later, it was supposed to become a free-flying space station in low-earth orbit before retirement of the current space station in 2030.

In coordination with NASA, Axiom Space has modified the plan.

Initially, Axiom planned to attach its first module, Habitat 1, to the space station, followed by three additional modules. Under the new scenario, the payload, power, and thermal modules will be launched first. This will enable the modules to join the current space station as early as 2028, becoming a free-flying station called Axiom Station.

“The International Space Station has provided a one-of-a-kind scientific platform for nearly 25 years,” says Dana Weigel, manager of the International Space Station program at NASA’s Johnson Space Center.

“As we approach the end of [the] space station’s operational life," she continues, "it’s critically important that we look to the future of [low-earth orbit] and support these follow-on destinations to ensure we continue NASA’s presence in microgravity, which began through the International Space Station.”

In free flight, Axiom will continue assembling the commercial destination, adding the Habitat 1 module, an airlock, the Habitat 2 module, and a research and manufacturing lab.

“We were ready to answer the call when NASA asked us to relook at our space station development plan,” Mark Greeley, Axiom Space COO and Axiom Station program manager, says in a statement from Axiom. “Our ongoing assessment of the assembly sequence revealed opportunities for flexibility and enhancements. With the International Space Station needing to protect for the ability to accommodate a deorbit vehicle on station, we were able to accelerate this work to support the program’s requirements.

“NASA has been extremely collaborative and supportive of the new plan as it addresses its deorbit operational concerns and preserves critical capabilities currently utilized on the International Space Station,” he adds. “This revised approach not only aligns with U.S. objectives but also delivers immediate value for our customers and investors.”

The Axiom's Payload Power Thermal Module primary structure is being constructed by Thales Alenia Space in Turin, Italy, and then moved to Houston by fall 2025, where the rest of the internal structure and systems will be integrated at Axiom Space facilities.

“Working with leading experts like Thales Alenia, who have a proven record in module development and a strong relationship with NASA, is integral to our operations and vision," Tejpaul Bhatia, Axiom Space chief revenue officer, says.

“By engaging and integrating with a network of partners from around the world, we access cutting-edge technologies and innovative solutions that enhance our capabilities and supply chain,” Bhatia adds. “Our customer base is truly global, including governments, private entities, and research institutions. This diversity enables us to meet a wide range of needs and reinforces our belief that space exploration is a collective endeavor for the benefit of all of humanity.”

Axiom has revised its plan for its commercial space station. Image via Axiom

Promising Houston sleep tech startup readies for big year of growth, work toward FDA clearance

HOUSTON INNOVATORS PODCAST EPISODE 268

There's a slew of treatment options for people living with sleep apnea. But, the bigger problem, as Meagan Pitcher realized during her time at the Texas Medical Center's Biodesign program, is that there's no easy way to reliably diagnose and determine a treatment plan for patients.

"We saw all of the companies trying to solve the problem of making the airway collapse less or make the air way wider — it might be surgery, might be medication, or nerve stimulation," Pitcher says on the Houston Innovators Podcast. "One of the things we found was that it was really hard to match a patient with sleep apnea with a good treatment for them. One of the reasons is it's hard to get an understanding of where the individual's site of collapse is as sleep medicine is currently practiced."

As Pitcher went through the TMC Biodesign program, she teamed up with her co-founders — CTO Onur Kilicand and CMO Britt Cross — to find a solution, and together they developed Bairitone Health. The company's technology provides at-home medical imaging using sonar sensing. The non-invasive device has the potential to replace the current standard of care, which is a surgical procedure.



This year, the company joined Activate Houston's inaugural cohort as the lone biotech company. Activate, which announced its expansion to Houston in 2023, helps hardtech founders develop and grow their companies from bench to commercialization, though it mostly focuses on industrial or climatetech innovators. In addition to this accomplishment, Bairitone Health was among the 2024 Houston Innovation Awards finalists.

While 2024 was successful for the company, next year should bring even more milestones for Bairitone, Pitcher says, including a seed round of funding that will support the growth of their team, fund early testing, and fuel Baritone's path toward FDA clearance.

"2025 is going to be a big year for Bairitone, especially around solidifying our regulatory plan. The device we're making is really low risk — we're not putting anything into the body, and we're potentially replacing a surgical procedure," Pitcher says. "We've always hypothesized that we'll have a 510(k) clearance with the FDA, but we're moving toward having our first meeting with the FDA to solidify those plans."

Bairitone's journey so far has been a uniquely Houston story, as Pitcher acknowledges.

"I really love Houston — especially for med tech. The medical center is just awesome, you have all these brilliant people coming in from the entire world to work at these institutions," Pitcher says. "It's kind of because of this atmosphere of excellence around health care, innovation, open mindedness, and collaboration — those are reasons why I really love working in Houston."

Top stories: Houston's most-read health tech news of 2024

year in review

Editor's note: As the year comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. In the health tech category on InnovationMap, top stories included startup funding raised, IPO plans, FDA clearance, and more. Be sure to click through to read the full story.

New report ranks Houston top market for life sciences

Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. Photo by Natalie Harms/InnovationMap

Thanks in large part to producing hundreds of college-trained professionals, Houston’s life sciences industry ranks among the top U.S. markets for talent in 2024.

In a report published by commercial real estate services company CBRE, Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. From 2017 to 2022, Houston notched a growth rate of 32.4 percent in this category.

In 2022, the University of Houston led the higher education pack in the region, graduating 746 people with a bachelor’s degree or above in biological or biomedical sciences, according to the report. Continue reading.

Houston innovator raises pre-seed funding for health care staffing platform

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

A Houston health care innovator is celebrating an oversubscribed round of pre-seed funding to improve on her startup's unique staffing platform.

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. The new platform, which cuts out the middleman and lowers staffing costs, raised $700,000 in pre-seed funding that will go toward further development of the technology.

"Healthcare organizations spend $26 billion annually to support a crippling dependence on third-party agencies for connecting with clinical staff," Ademuyewo says in a news release. "Technological solutions that are pointed precisely to streamline and strengthen the relationships between highly specialized clinicians and their future employers are vital to alleviating this detrimental dependance, and central to our mission." Continue reading.

Houston regenerative medicine company to IPO, move toward more human trials

FibroBiologics will IPO this week. Photo via Getty Images

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.” Continue reading.

Houston organizations identify promising life science cos. at annual event

The Rice Alliance and BioHouston acknowledged innovations from a dozen promising health tech companies. Photo via Rice University

For the 13th year, the Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship celebrated innovative companies from around the world that are creating new treatments and solutions to today's biggest health care challenges.

This week, over 40 companies presenting their innovations across cancer, cardiovascular disease, biotechnology, and more. Nearly 700 venture capitalists, corporate innovation groups, angel networks, industry leaders, academics, service providers, and others attended the event on November 7 at Rice's BioScience Research Collaborative in the Texas Medical Center.

Just like in previous years, the event ended with the announcement of the 10 companies that were deemed "most promising" based on their pitches and technologies. Of the 10 companies named, six are headquartered in Houston and an additional two startups on the list have a presence here. Continue reading.

FDA greenlights Houston surgery robotics company's unique technology

EndoQuest Robotics secured an Investigational Device Exemption from the FDA for its clinical study. Photo via Getty Images

A Houston surgical robotics company has gotten a Investigational Device Exemption from the FDA to go forward with human trials.

This news allows EndoQuest Robotics to begin its Prospective Assessment of a Robotic-Assisted Device in Gastrointestinal Medicine (PARADIGM) study, which will be conducted at leading United States health care facilities, including Brigham and Women’s Hospital (Boston), Mayo Clinic (Scottsdale), Cleveland Clinic (Cleveland), AdventHealth (Orlando), and HCA Healthcare (Houston). The study will include surgeries on 50 subjects, who will hopefully begin to enroll in January.

“The foundational thesis is we're trying to make sure that the world's largest medical center is also the world's largest med tech innovation center,” Eduardo Fonseca, interim CEO of EndoQuest Robotics, tells InnovationMap. Continue reading.

View All Listings